Quantcast

Latest Treatment for depression Stories

2009-04-30 15:46:49

U.S. scientists say they have identified an acid-sensitive brain protein that might become a new drug target for the treatment of depression Investigators at the University of Iowa led by researcher Matthew Coryell and Dr. John Wemmie said they determined disrupting acid-sensitive ion channel-1a produces antidepressant-like effects in mice. They said that finding might one day benefit people who don't respond to traditional antidepressants or who can't tolerate their side effects. Although...

2009-04-29 08:30:53

People with depression often excluded from clinical studies and tend not to fare as well as study participantsFindings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health. Published in the May issue of the American Journal of Psychiatry, the study suggests only a small percentage of people with depression...

2009-04-21 09:08:00

Novel device for the treatment of depression named one of 2008's top medical device innovations MALVERN, Pa., April 21 /PRNewswire/ --- NeuroStar(R) TMS (Transcranial Magnetic Stimulation) Therapy system, the first and only non-systemic and non-invasive treatment cleared by the FDA for Major Depressive Disorder, is a recipient of the prestigious Medical Design Excellence Award (MDEA). The award will be presented in June at the twelfth annual MD&DI (Medical Device & Diagnostic...

2009-04-07 06:58:00

BRIDGEWATER, N.J., April 7 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that Aplenzin(TM) (bupropion hydrobromide) extended-release tablets, an effective bupropion therapy for the treatment of major depressive disorder (MDD), is now available by prescription in the United States for adults ages 18 and older. Aplenzin differs from other generic and branded bupropion antidepressants because it provides a unique HBr salt extended-release formulation, offering prescribers and...

2009-03-20 12:38:00

NEW YORK, March 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Lexapro (escitalopram oxalate) for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, 12 - 17 years of age. Lexapro is only the second antidepressant to be approved for the treatment of MDD in adolescents, a medical condition that...

2009-02-09 09:26:42

Much has been written about the link between drugs used to treat depression and the risk of suicide. A study conducted by the Food and Drug Administration (FDA) in 2007 suggested a lower risk among the elderly, no increased risk among adults, and an increased risk among those age 25 and younger. Those findings led to black box warnings on the drugs alerting people to the possibility of an elevated risk in children and young people. Now a new meta-analysis conducted by investigators from the...

2009-01-15 15:22:07

In a national clinical trial, adolescents with moderate to severe depression first given a placebo treatment and then an antidepressant medication alone or in combination with therapy responded just as well over the long term as participants who received active treatment throughout the study, UT Southwestern Medical Center researchers report.Researchers found that at the end of nine months, children and teenagers first given placebo treatment for 12 weeks and then given active treatment had a...

2009-01-05 07:10:00

ANN ARBOR, Mich., Jan. 5 /PRNewswire-USNewswire/ -- When Lamont Christian returned from war, he often felt angry, afraid and unworthy. Years later, Christian found himself living in a homeless shelter, a sign that time had not healed his emotional wounds. He went to the VA Ann Arbor Healthcare System for help, and there, he learned the root of his problems: he was suffering from depression, post- traumatic stress disorder and anger management problems. Now, he wants others to learn...

2008-12-22 07:00:00

NEW YORK and PARIS, Dec. 22, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced that they have entered into a definitive collaboration agreement to develop and commercialize F2695 in the United States and Canada. F2695 is a proprietary selective norepinephrine and serotonin reuptake inhibitor that is being developed by Pierre Fabre for the treatment of depression and other central nervous system disorders. (Logo:...

2008-11-06 09:00:12

MALVERN, Pa., Nov. 6 /PRNewswire/ -- Neuronetics, Inc. announced today that a new health economic study evaluating the cost effectiveness of its NeuroStar TMS Therapy system in the treatment of depression was presented at the U.S. Psychiatric and Mental Health Congress in San Diego last week. This study is the largest and most comprehensive cost effectiveness study to date of TMS Therapy in patients with major depression who have failed to achieve benefit from prior antidepressant treatment,...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related